Hemoglobin allostery and pharmacology

Bellelli, Andrea; Tame, J.R.H.

doi:10.1016/j.mam.2021.101037

Cited by 15 publications

(11 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hb contains four different ligand binding sites: heme, exposed cysteine residues, DPG binding sites and Bohr residues [ 59 ]. Changes in any binding site can induce corresponding structural alterations in Hb, affecting the balance between the “T” (tense) and “R” (relaxed) states, subsequently resulting in altered oxygen affinity, called “allosteric effects” [ 57 ].…”

Section: Oxygen-releasing Biomaterialsmentioning

confidence: 99%

Oxygen-releasing biomaterials for chronic wounds breathing: From theoretical mechanism to application prospect

Chang

2023

Materials Today Bio

View full text Add to dashboard Cite

Section: Oxygen-releasing Biomaterialsmentioning

confidence: 99%

Oxygen-releasing biomaterials for chronic wounds breathing: From theoretical mechanism to application prospect

Chang

2023

Materials Today Bio

View full text Add to dashboard Cite

“…O 2 binds to heme Fe(II) atoms, transforming the quaternary structure of Hb from a deoxygenated (T) state to a relaxed ligand-bound (R) state, 8 The R-to-T state transition is the reversible electrostatic binding of allosteric effectors such as hydrogen ions, carbon dioxide, and 2,3-bisphosphoglycerate (DPG) to two β subunits (pockets), and the combined effectors reduce the Hb oxygen affinity and promote oxygen unloading. 9,10 In addition to oxygen transport, Hb also has other important physiological functions, such as blood heat exchange, catabolism of one porphyrin to produce CO to regulate vascular tone 11 and to produce bilirubin to scavenge free radicals simultaneously, scavenging and transporting NO, 12−14 etc.…”

Section: Hb-based Oxygen Carriersmentioning

confidence: 99%

“…Human hemoglobin has a molecular weight of 64 500 Da and is composed of two α and two β subunits, each containing a heme group that can transport an oxygen molecule (Figure ). O 2 binds to heme Fe(II) atoms, transforming the quaternary structure of Hb from a deoxygenated (T) state to a relaxed ligand-bound (R) state, The R-to-T state transition is the reversible electrostatic binding of allosteric effectors such as hydrogen ions, carbon dioxide, and 2,3-bisphosphoglycerate (DPG) to two β subunits (pockets), and the combined effectors reduce the Hb oxygen affinity and promote oxygen unloading. , …”

Section: Hb-based Oxygen Carriersmentioning

confidence: 99%

Research Progress in Oxygen Carrier Design and Application

Ye,

Zheng,

Chen

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Ischemia or hypoxia can lead to pathological changes in the metabolism and function of tissues and then lead to various diseases. Timely and effective blood resuscitation or improvement of hypoxia is very important for the treatment of diseases. However, there is a need to develop stable, nontoxic, and immunologically inert oxygen carriers due to limitations such as blood shortages, different blood types, and the risk of transmitting infections. With the development of various technologies, oxygen carriers based on hemoglobin and perfluorocarbon have been widely studied in recent years. This paper reviews the development and application of hemoglobin and perfluorocarbon oxygen carriers. The design of oxygen carriers was analyzed, and their application as blood substitutes or oxygen carriers in various hypoxic diseases was discussed. Finally, the characteristics and future research of ideal oxygen carriers were prospected to provide reference for follow-up research.

show abstract

“…Patients often suffer from blood abnormalities, platelet dysfunction, and other diseases, such as abnormal liver function and anemia, that change the number and state of their platelets ( Newsome et al, 2018 ; Bellelli and Tame, 2022 ). An insufficient number of platelets or dysfunction in them might lead to thrombosis-related disorders ( Zhou et al, 2021 ).…”

Section: Biomaterials-mediated Therapy Through Activation Of Platelet...mentioning

confidence: 99%

Biomaterials-Mediated Tumor Infarction Therapy

Tong

Zhao

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Agents for tumor vascular infarction are recently developed therapeutic agents for the vascular destruction of tumors. They can suppress the progression of the tumor by preventing the flow of nutrition and oxygen to its tissues. Agents of tumor vascular infarction can be divided into three categories according to the differences in their pathways of action: those that use the thrombin-activating pathway, fibrin-activating pathway, and platelet-activating pathway. However, poor targeting ability, low permeation, and potential side-effects restrict the development of the corresponding drugs. Biomaterials can subtly avoid these drawbacks to suppress the tumor. In this article, the authors summarize currently used biomaterials for tumor infarction therapy with the goal of identifying its mechanism, and discuss outstanding deficiencies in methods of this kind.

show abstract

Hemoglobin allostery and pharmacology

Cited by 15 publications

References 97 publications

Oxygen-releasing biomaterials for chronic wounds breathing: From theoretical mechanism to application prospect

Oxygen-releasing biomaterials for chronic wounds breathing: From theoretical mechanism to application prospect

Research Progress in Oxygen Carrier Design and Application

Biomaterials-Mediated Tumor Infarction Therapy

Contact Info

Product

Resources

About